Overview

European Phase III Study of APD421 in PONV

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Phase:
Phase 3
Details
Lead Sponsor:
Acacia Pharma Ltd